|
|
Name: |
Ding Jian
|
Education: |
Ph.D
|
|
Positions: |
Academician of the Chinese Academy of Engineering, PI
|
Academic title: |
Professor
|
Phone: |
+86-21-50806079
|
Fax: |
86-21-50807088
|
E-mail: |
jding@simm.ac.cn
|
Personal Website: |
|
Postal Code: |
201203
|
Mailing Address: |
555 Zu Chong Zhi Road, Zhang Jiang Hi-Tech Park, Pudong, Shanghai, P.R.China
|
|
| Resume: |
|
EDUCATION
1978.10-1986.9 Jiangxi Medical University, Nanchang, China, B.S. in Pathology
1980.9-1983.9 Medical University of China, Shenyang, China, M.A. in Pathology
1986.10-1992.1 Kyushu University, Fukuoka, Japan, Ph.D. in Pathology
WORK EXPERIENCE
1986.10-1992.1 Kyushu University Visiting scholar
1992.2-1994.2 Shanghai Institute of Materia Medica Postdoctoral fellow
1994.2-now Shanghai Institute of Materia Medica Principal Investigator, Professor
1996.8-2004.11 Shanghai Institute of Materia Medica Deputy Director
2004.12-2014.3 Shanghai Institute of Materia Medica Director
2001.1-2003.1 National Center for Drug Screening Director, Professor
2005.1-2012.1 State key Laboratory of Drug Research Director, Professor
|
| Research Directions |
|
Dr. Ding’s laboratory is mainly focused on:(1) discovery and development of molecularly targeted anticancer drugs targeting tyrosine kinases,PI3K/mTOR pathway, epigenetic modulators and tumor angiogenesis regulators; (2) exploring molecular mechanisms of anticancer drugs, particularly signaling transduction and molecular basis of drug resistance; (3) characterizing genomics-based new targets for the proof of concept of novel cancer therapies; (4) discovery of biomarkers for molecularly targeted therapies.
|
| Social Titles |
|
2006.12, Acta Pharmacologica Sinica,Editor-in-chief ;
2007, Chinese pharmaceutical association,Executive member of the council;
2007,Committee of Anti-Cancer Agent,Executive member of the council;
2007,Council of the Chinese Society of Pharmacology,Executive member of the council;
2007.1,Cancer Biology & Therapy,Editorial board member;
2007.1,European Journal of Pharmacology,Editorial board member;
2007.1-, Journal of Ethno pharmacology, Editorial board member;
2009.11-,Journal of Biological Chemistry, Editorial board member;
2012-, Molecular Pharmacology, Editorial board member.
|
| Awards & Honors |
2013, National Natural Science Award
2011 ,Outstanding director of research institute(Shanghai)
2011, "Eleventh Five-Year" National Science and Technology Award for outstanding contribution to implementation of the plan
2009, National Natural Science Award, 2rd prize
2008, Prize of Scientific and Technological Progress of Ho Leung Ho Lee Foundation
2007, 2010 National Natural Science Award(Shanghai)
2006, Wu Jieping Medical-Paul Janssen Pharmaceutical Research Prize
2005, Top ten scientific and technological elites (Shanghai)
2004, 2005 Excellent Supervisor of Chinese Academy of Sciences
2003, National Science &Technology Award, 2rd prize
2003, Shanghai Science & Technology Award
2001, Fourth International Debio-CCRF Award, 1st Prize
|
| Achievements |
Dr. Ding has led the discovery and development of a number of anticancer drugs. Three candidate drugs,K-001 is undergoing Phase II trial which is targeted on hepatocellular carcinoma , and a toposomrase inhibitor and a kinase inhibitor of FGFR and VEGFR (known as Simmite can and AL3810 respectively),are undergoing Phase I trial.Another six drug candiates, including a selective PI3Kα inhibitor CHY33, and a highly selective c-Met inhibitor SIMM244 and so on, are undergoing preclinical evaluation. These candidate drugs all come from an in-house platform that provides comprehensive molecule, cell, and animal-based assays for the assessment of inhibitors targeting tyrosine kinases, PI3K/mTOR signaling molecules, epigenetic modulators and topoisomerases.
Ding’s team has systematically revealed the anti-tumor mechanism of more than ten innovative candidate compounds or drugs like AL3810, Salvicine , pseudolaric acid, MT119, X-287, C9 and JG3. Several molecular biomarkers, such pIgR as a prognostic biomarker for hepatocellular carcinoma, and p27/KIP1 as a predictive biomarker for mTOR inhibitors have been discovered. More than 240 papers have been published in journals including J Natl Cancer Inst, Trends Pharmacol Sci, Cancer Res, Oncogene, Clin Cancer Res, Cancer Mol Ther, Mol Pharmacol, Int J Cancer, J Biol Chemetc., with a total citation over 3000 times. Over 120 patents have been authorized or filed for application.
|
| Grants & Research Projects |
1. Ministry of Health Chemical innovative drug R & D system,Project Leader,2012.1-2015.12;
2. Chinese Academy of Sciences Denmark donated compound sample library,Project Leader,2008.1-2012.12;
3. Ministry of Health Chemical innovative drug R & D system,Project Leader,2009.1-2010.12;
4. Chinese Academy of Sciences Multi-target mechanism of action based on protein structure and function of the drug,Project Leader, 2011.1-2013.12
5. National Natural Science Foundation of China Discover the molecular targets for anticancer drugs and its mechanism,Project Leader, 2011.1-2013.12
6. Ministry of Health Chinese Medicine Technology Innovation Strategic Alliance,Project Leader,2010.1-2012.12
|
| Pubilcations |
|
1. Ai J, Tang QJ, Wu YL, Xu Y, Feng T, Zhou RY, Chen Y, Gao X, Zhu QF, Yue XH, Pan QN, Xu SY, Li J, Huang M, Daugherty-Holtrop J, He YZ, Xu HE, Fan J*, Ding J*, Geng M*. The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. J Natl Cancer Inst. 103:1696-712, 2011
2. Jiang Y., Miao ZH*., Xu L., Yu B., Gong JX., Tong LJ., Chen Y., Zhou ZL., Liu HC., Wang Y., Guo YW., Ding J*. Drug transporter-independentliver cancer cell killing by marine steroid methyl spongoate via intrinsic and extrinsic apoptosis pathways. J BiolChem 286:26461-9, 2011
3. Zhang J, Xin X, Chen Q, Xie Z, Gui M, Chen Y, Lin L, Feng J, Li Q, Ding J*, Geng M*. Oligomannurarate sulfate sensitizes cancer cells to doxorubicin by inhibiting atypical activation of NF-κB via targeting of Mre11. Int J Cancer. 130: 467–477, 2012
4. Chen G, Chen SM, Wang X, Ding XF, Ding J*, Meng LH*. Inhibition of Chemokine (CXC Motif) Ligand 12/Chemokine (CXC Motif) Receptor 4 Axis CXCL12/CXCR4)-mediated Cell Migration by Targeting Mammalian Target of Rapamycin (mTOR) Pathway in Human Gastric Carcinoma Cells. J Biol Chem. 287(15):12132-41, 2012 .
5. Chen SM, Liu JL, Wang X, Liang C, Ding J*, Meng LH*. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. BiochemPharmacol. 83(9):1183-94, 2012.
6. Yu B, Li MH, Wang W, Wang YQ, Jiang Y, Yang SP, Yue JM, Ding J*, Miao ZH*. Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model. J Mol Med (Berl). 90(8):971-81,2012.
7. Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, Xi Y, Shen Y, Geng M, Wang Y, Jiang H, Luo C, Lin L*, Ding J*. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and antitumor activity via targeting VEGFR, FGFR, and PDGFR. J Cell Mol Med. 16(10):2321-2330, 2012.
8. Zhu CH., Chen Q., XieZQ., Ai J., Tong LJ., Ding J*., Geng MY*. The role of histone deacetylase 7 (HDAC 7) in cancer cell proliferation: regulation on c-Myc. J Mol Med 89: 279-89, 2011
9. Zhang ZX., Meng T., Yang N., Wang W., Xiong B., Chen Y., Ma LP., Shen JK., Miao ZH*, Ding J*. MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation. Inter J Cancer 129: 214-24, 2011.
10. Chen G, Yang N, Wang X, Zheng SY, Chen Y, Tong LJ, LI YX, Meng L*., Ding J*.Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer. J Mol Med 88: 941-52, 2010
11. Li M, Miao ZH, Chen Z, Chen Q, Gui M, Lin LP, Sun P, Yi YH, Ding J*. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase II? by unique interference with its DNA binding and catalytic cycle. Ann Oncol 21: 597-607, 2010.
12. Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J*. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J PharmacolExpTher. 334:830-8, 2010
13. Lu JJ.,Meng LH*., Shankavaramb UT., Zhu CH., Tong LJ., Chen G., Lin LP., Weinsteinc JN., Ding J*. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. BiochemPharmacol 80: 22-30, 2010.
14. Yu B, Miao ZH, Jiang Y, Li MH, Yang N, Li T, Ding J*. c-Jun Protects Hypoxia-Inducible Factor-1{alpha} from Degradation via Its Oxygen-Dependent Degradation Domain in a Nontranscriptional Manner. Cancer Res. 69:7704-12, 2009
15. Li Z, Zhou ZL, Miao ZH, Lin LP, Feng HJ, Tong LJ, Ding J*, Li YC*. Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents. J Med Chem. 52:5115-23, 2009
16. Zhu H, Miao ZH*, Huang M, Feng JM, Zhang ZX, Lu JJ, Cai YJ, Tong LJ, Xu YF, Qian XH, Ding J*. Naphthalimides induce G2 phase arrest in HCT-116 cells via ATM-activated Chk2-executed pathway. Neoplasia 11: 1226–34. 2009
17. Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, Meng LH, Ding J*. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS One. 2009;4(3):e4881.
18. Ren X, Dai M, Lin LP, Li PK, Ding J*. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. Br J Pharmacol. 156 :1228-38, 2009.
|
|
|
|
|
|
|
|
